Keywords: fda, clears, astellas, vaprisol, hypervolemic, hyponatremia, subsidiary

FDA clears Astellas' Vaprisol for hypervolemic hyponatremia

Article | 12 March 2007

Print This

The US subsidiary of Japan's Astellas Pharma has received Food and Drug Administration approval for its Vaprisol (conivaptan HCl injection), ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in